DABUR2026-06-15DABUR2026-06-15ActionsTakenOrOrdersPassedDomain1DABUR2026-06-15ActionsTakenOrOrdersPassedDomain1PersonsAgainstWhomActionsTakenOrOrdersPassedDomain1DABUR2026-06-15SignatoriesDomain1xbrli:pureDABURDabur India Limited500096NOTLISTEDINE016A01026NewAction(s) taken or orders passed (sub-para 20)false2026-06-1003:29:002026-06-15Sanctions ImposedRegulatory AuthorityUnited States Food and Drug Administration1Listed Entity (Self)Dabur India LimitedUS FDA has issued an Import Alert (IA) 66-40US FDA had inspected Company's manufacturing plant situated at Silvassa, Dadra and Nagar Havelli and had indentified certain deficiencies on account of data integrity and maintenance lapses. Upon conclusion of the inspection, the Company had received inspectional observations to which responses were suitably submitted to US FDA. Now, pursuant to observations noted by the authority, review of the Company's responses and Establishment Inspection Report (EIR), US DA had issued an Import Alert (IA) 66-40 on June 10, 2026, for drugs manufactured by the Company at the aforesaid plant.2026-06-10US FDA had inspected Company's manufacturing plant situated at Silvassa, Dadra and Nagar Havelli and had indentified certain deficiencies on account of data integrity and maintenance lapses. Upon conclusion of the inspection, the Company had received inspectional observations to which responses were suitably submitted to US FDA. Now, pursuant to observations noted by the authority, review of the Company's responses and Establishment Inspection Report (EIR), US DA had issued an Import Alert (IA) 66-40 on June 10, 2026, for drugs manufactured by the Company at the aforesaid plant.Not applicableThere is no impact on financial, operation or other activities of the Company due to this order. The order concerns to only a small part of our manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, in relation to private label products, which generates insignificant revenue for the Company. Domestic products are not covered and not impacted by this order. The aforesaid plant continues to be operational. We are continuing to engage with the US FDA authority by providing corrective and preventive action plans along with proactive and strong action on the ground to fix the identified gaps. In addition, multiple internal and external independent third party testing has shown no out of specification or any other concerns with any of Company’s products. We remain committed to product quality and consumer safety despite this one-off incident. We operate sites across the globe and are taking effective action to implement alternate sourcing strategies for our US customers.There is no violation(s)/contravention(s) committed or alleged to be committed.US FDA has issued an Import Alert (IA) 66-40US FDA has issued an Import Alert (IA) 66-40We are continuing to engage with the US FDA authority by providing corrective and preventive action plans along with proactive and strong action on the ground to fix the identified gaps. In addition, multiple internal and external independent third party testing has shown no out of specification or any other concerns with any of Company’s products. We remain committed to product quality and consumer safety despite this one-off incident. We operate sites across the globe and are taking effective action to implement alternate sourcing strategies for our US customers.Ashok Kumar JainCompliance Officer2026-06-15New Delhi